Skip to main content

Articles

Page 13 of 13

  1. In order to evaluate the critical components of the process necessary to preserve clinical plasma samples collected at research sites for proteomic analysis, various collection and preservation protocols with ...

    Authors: Jeffrey D. Hulmes, Deidra Bethea, Keith Ho, Shu-Pang Huang, Deborah L. Ricci, Gregory J. Opiteck and Stanley A. Hefta
    Citation: Clinical Proteomics 2004 1:21117
    Content type: Serum/Plasma Proteome Published on:

  2. Many protein functions are conferred by posttranslational modifications, which allow proteins to perform specific cellular tasks. Protein microarrays enable specific detection of posttranslational modification...

    Authors: Virginia Espina, Emanuel F. Petricoin III, Lance A. Liotta and David Geho
    Citation: Clinical Proteomics 2004 1:11091
    Content type: Brief Technical Report Published on:

  3. Protein microarrays have been recently employed for signal pathway profiling and high-throughput protein expression analysis. Reversephase arrays, where the array consists of immobilized analytes and lysates h...

    Authors: Valerie S. Calvert, Yihui Tang, Vince Boveia, Julie Wulfkuhle, Amy Schutz-Geschwender, D. Michael Olive, Lance A. Liotta and Emanuel F. Petricoin III
    Citation: Clinical Proteomics 2004 1:11081
    Content type: Brief Technical Report Published on:

  4. The purpose of this phospho-proteomics study was to demonstrate the broad analysis of cellular protein phosphorylation in cells and tissue as a means to monitor changes in cellular states. As a cancer model, h...

    Authors: David R. Stover, Jennifer Caldwell, Jarrod Marto, Karen Root, Juergan Mestan, Michael Stumm, Olga Ornatsky, Chris Orsi, Nina Radosevic, Linda Liao, Doriano Fabbro and Michael F. Moran
    Citation: Clinical Proteomics 2004 1:11069
    Content type: Molecular Targets Published on:

  5. Methotrexate has been a clinical agent used in cancer, immunosuppression, rheumatoid arthritis and other highly proliferative diseases for many years, yet its underlying molecular mechanism of action in these ...

    Authors: Leticia M. Toledo-Sherman, Leroi Desouza, Christopher M. Hosfield, Linda Liao, Kelly Boutillier, Paul Taylor, Shane Climie, Linda McBroom-Cerajewski and Michael F. Moran
    Citation: Clinical Proteomics 2004 1:11045
    Content type: Molecular Targets Published on:

  6. The tissue specificity of creatine kinase (CK-MB) has been shown not to be absolute for the myocardium. Unexplained increases of plasma creatine kinase (CK-MB) occur in patients with skeletal muscle disease, c...

    Authors: Vincent Ricchiuti, Ellen M. Voss, Arthur Ney, Mark Odland and Fred S. Apple
    Citation: Clinical Proteomics 2004 1:11033
    Content type: Biomarker Discovery and Profiling Published on:

  7. With increased interest in clinical proteomics—the comparative investigation of differential protein expression patterns for use in the diagnostic and prognostic assessment of disease states—the demand for tec...

    Authors: Urban A. Kiernan, Dobrin Nedelkov, Kemmons A. Tubbs, Eric E. Niederkofler and Randall W. Nelson
    Citation: Clinical Proteomics 2004 1:11007
    Content type: Serum/Plasma Proteome Published on:
Submit manuscript

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.8
    5-year Journal Impact Factor: 3.9
    Source Normalized Impact per Paper (SNIP): 0.831
    SCImago Journal Rank (SJR): 1.015

    Speed 2023
    Submission to first editorial decision (median days): 10
    Submission to acceptance (median days): 159

    Usage 2023
    Downloads: 434,196
    Altmetric mentions: 385

Clinical Proteomics

ISSN: 1559-0275